Ceftriaxone
- Generic Name
- Ceftriaxone
- Brand Names
- Rocephin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18N8O7S3
- CAS Number
- 73384-59-5
- Unique Ingredient Identifier
- 75J73V1629
- Background
Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S...
- Indication
Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabil...
- Associated Conditions
- Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial
- Associated Therapies
- -
Antibiotic Treatment of Multiple Erythema Migrans
- Conditions
- Interventions
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2017-05-05
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 500
- Registration Number
- NCT01163994
- Locations
- 🇸🇮
UMC Ljubljana, Department of Infectious Diseases, Ljubljana, Slovenia
The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)
- Conditions
- Interventions
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Harold Wiesenfeld
- Target Recruit Count
- 233
- Registration Number
- NCT01160640
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Allegheny County Health Department Sexually Transmitted Diseases Clinic, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Mercy Hospital, Pittsburgh, Pennsylvania, United States
Chlamydia Trachomatis Immunology and Vaccinology Study
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Harold Wiesenfeld
- Target Recruit Count
- 347
- Registration Number
- NCT01150747
- Locations
- 🇺🇸
Mercy Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Doxycycline and Ceftriaxone in Suspected Early Lyme Neuroborreliosis
- Conditions
- Interventions
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 200
- Registration Number
- NCT00942006
- Locations
- 🇸🇮
UMC Ljubljana, Department of Infectious Diseases, Ljubljana, Slovenia
Study on Early Lyme Neuroborreliosis
- First Posted Date
- 2009-06-01
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 50
- Registration Number
- NCT00910533
- Locations
- 🇸🇮
UMC Ljubljana, Department of Infectious Diseases, Ljubljana, Slovenia
Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Kaohsiung Veterans General Hospital.
- Target Recruit Count
- 24
- Registration Number
- NCT00895089
- Locations
- 🇨🇳
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis
- Conditions
- Interventions
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Research Foundation for Mental Hygiene, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00591318
- Locations
- 🇺🇸
NYS Psychiatric Institute, New York, New York, United States
Ceftriaxone in the Management of Bipolar Depression
- Conditions
- Interventions
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 5
- Registration Number
- NCT00566111
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder
- Conditions
- First Posted Date
- 2007-08-07
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Institute of Mental Health (NIMH)
- Registration Number
- NCT00512616
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 622
- Registration Number
- NCT00509106
- Locations
- 🇵🇱
Inestigational Site, Warszawa, Poland
🇺🇦Investigational site, Kyiv, Ukraine
🇵🇱Investigtional Site, Krakow, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.